MOTS-c and skeletal-muscle preservation

A peptide inside mitochondrial DNA

MOTS-c is a 16-amino-acid peptide encoded within MT-RNR1, the mitochondrial 12S ribosomal RNA gene. Its location is unusual: most protein and peptide instructions reside in the nucleus. The 2023 review of MOTS-c biology brings together the work on its origin, stress responses, metabolism and aging.

I expected a molecule discussed in terms of muscle performance to have a simple performance story. Instead, the molecular record contains several kinds of action, and the most interesting recent target behaves differently across tissues. That complexity earns a closer look.

The best-characterized pathway involves inhibition of the folate cycle and purine synthesis, accumulation of a metabolite called AICAR, and activation of AMPK, a cellular energy sensor. The resulting metabolic changes have been studied chiefly in cells and animals, including muscle glucose handling and insulin sensitivity. Human efficacy of administered MOTS-c remains unestablished.

CK2 activity by tissue

In the 2024 CK2 investigation, MOTS-c directly bound and activated casein kinase 2 in cell-free systems. Experiments in young, aged, high-fat-diet and immobilized mice connected the peptide with prevention of skeletal-muscle atrophy and enhanced muscle glucose uptake.

The tissue split resists my urge to simplify. The account describes CK2 activation in muscle and suppression in fat. An explanation that simply says MOTS-c turns metabolism up loses something important about where the effects occurred.

For an AgeDefy question, disuse is particularly revealing. The immobilized-mouse work asks about retaining muscle through a challenge, which is a more precise ambition than an overall reversal of aging. Preserving muscle through disuse strikes me as an experiment worth doing. It still needs a human intervention record before it can support a claim about preserving muscle in people.

Running, grip strength and gait

The 2021 physical-capacity experiments reported improved treadmill running capacity, grip strength and gait in aged mice. The older mice were 22–23.5 months old, and the reported treadmill finding had P=0.000002. The same research established exercise-inducibility of endogenous MOTS-c.

Those functional outcomes give the preservation argument some weight. A mouse running farther is a more tangible result than a changed molecular marker. It remains a mouse result, with experimental conditions and an administered substance that have no established equivalent human efficacy trial here.

“Exercise mimetic” is the term used for compounds studied for reproducing some responses to exercise. The term makes me uneasy when it starts standing for exercise’s whole value. This paper measures particular responses; the human question about administered MOTS-c stays open.

MOTS-c in stressed cells

In human and mouse cell experiments, metabolic stress caused MOTS-c to move toward the nucleus and regulate gene expression through AMPK-dependent processes, including interaction with NRF2 and antioxidant-response-element genes. That gives the peptide a role in communication as well as metabolism.

I enjoy contemplating that journey: a message encoded in mitochondrial DNA can reach the place where most of the cell’s genetic instructions are stored. For this site’s question, though, the cells offer an explanation worth pursuing. The physical-capacity findings still have to be judged in the animals where they were measured.

MOTS-c safety, approval, anti-doping

The human safety profile of administered MOTS-c has not been established in completed clinical efficacy or safety trials. Human pharmacokinetic measurements, including a validated half-life and dose-response, are also missing. Animal regimens provide no validated human schedule.

MOTS-c has no FDA approval, including as a compounded medication. Research-labelled supplies remain sold for laboratory work, separately from compounded prescription preparations following clinical assessment. Laboratory supplies are not regulated as pharmaceuticals for identity, purity or sterility. MOTS-c is prohibited in governed sport under anti-doping hormone and metabolic-modulator categories.

The literature also raises a mitochondrial genetic variant, m.1382A>C, associated with impaired glycemic control, alongside ancestry-dependent exercise responses. Some mechanistic findings await replication and some human biomarker studies are small. A uniform-response story earns my suspicion when even the biological background may vary.

CARE CONTEXT / EVIDENCE BOUNDARY

A clinical route does not strengthen the human record

At mypromise.com, Promise Peptides prescribes compounded MOTS-c after a licensed U.S. clinician has assessed the individual case; that clinician can decline to prescribe. Its patients must be in the United States, and its options depend on the patient's state and the treatment under consideration. Its compounded MOTS-c medication has no FDA approval, and this clinical route does not fill the human efficacy or safety gaps in the literature.

The hemodialysis patients

The human association deserves its own space. In a multicenter cohort of 94 chronic hemodialysis patients, circulating MOTS-c was associated with a composite endpoint of all-cause mortality and non-fatal cardiovascular events over a median 26.5 months. Adding it to the risk model improved ROC AUC from 0.727 to 0.743, a measure of the model’s discrimination.

The study measured the peptide already circulating in the participants. It did not assign MOTS-c treatment. Risk prediction in dialysis patients is a worthwhile question in its own right. I’m less comfortable borrowing that association for treatment claims about function or survival.

That is why the comparison with NAD+ spends so much time on the kinds of human evidence available. A human association and a randomized precursor trial can both be informative while answering different questions.